These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 18406882)
1. A novel MRI marker for prostate brachytherapy. Frank SJ; Stafford RJ; Bankson JA; Li C; Swanson DA; Kudchadker RJ; Martirosyan KS Int J Radiat Oncol Biol Phys; 2008 May; 71(1):5-8. PubMed ID: 18406882 [TBL] [Abstract][Full Text] [Related]
2. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy. Frank SJ; Tailor RC; Kudchadker RJ; Martirosyan KS; Stafford RJ; Elliott AM; Swanson DA; Sing D; Choi J; Mourtada F; Ibbott GS Med Dosim; 2011; 36(2):200-5. PubMed ID: 20537886 [TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging (MRI) markers for MRI-guided high-dose-rate brachytherapy: novel marker-flange for cervical cancer and marker catheters for prostate cancer. Schindel J; Muruganandham M; Pigge FC; Anderson J; Kim Y Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):387-93. PubMed ID: 23433797 [TBL] [Abstract][Full Text] [Related]
4. Accuracy of seed reconstruction in prostate postplanning studied with a CT- and MRI-compatible phantom. De Brabandere M; Kirisits C; Peeters R; Haustermans K; Van den Heuvel F Radiother Oncol; 2006 May; 79(2):190-7. PubMed ID: 16707176 [TBL] [Abstract][Full Text] [Related]
5. Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis. Al-Qaisieh B; Smith DW; Brearley E; St Clair S; Bownes P Radiother Oncol; 2007 Aug; 84(2):140-7. PubMed ID: 17588696 [TBL] [Abstract][Full Text] [Related]
6. Update of prostate magnetic resonance imaging at 3 T. Kim CK; Park BK J Comput Assist Tomogr; 2008; 32(2):163-72. PubMed ID: 18379296 [TBL] [Abstract][Full Text] [Related]
7. MRI/TRUS data fusion for brachytherapy. Daanen V; Gastaldo J; Giraud JY; Fourneret P; Descotes JL; Bolla M; Collomb D; Troccaz J Int J Med Robot; 2006 Sep; 2(3):256-61. PubMed ID: 17520640 [TBL] [Abstract][Full Text] [Related]
8. Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer. Haack S; Nielsen SK; Lindegaard JC; Gelineck J; Tanderup K Radiother Oncol; 2009 May; 91(2):187-93. PubMed ID: 18977049 [TBL] [Abstract][Full Text] [Related]
10. Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI markers for MRI-based prostate postimplant assessment. Lim TY; Kudchadker RJ; Wang J; Stafford RJ; MacLellan C; Rao A; Ibbott GS; Frank SJ Med Phys; 2016 Jul; 43(7):4312. PubMed ID: 27370146 [TBL] [Abstract][Full Text] [Related]
11. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Aime S; Castelli DD; Crich SG; Gianolio E; Terreno E Acc Chem Res; 2009 Jul; 42(7):822-31. PubMed ID: 19534516 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy. Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887 [TBL] [Abstract][Full Text] [Related]
13. MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy. Lim TY; Stafford RJ; Kudchadker RJ; Sankaranarayanapillai M; Ibbott G; Rao A; Martirosyan KS; Frank SJ Phys Med Biol; 2014 May; 59(10):2505-16. PubMed ID: 24778352 [TBL] [Abstract][Full Text] [Related]
14. Sequential comparison of seed loss and prostate dosimetry of stranded seeds with loose seeds in 125I permanent implant for low-risk prostate cancer. Saibishkumar EP; Borg J; Yeung I; Cummins-Holder C; Landon A; Crook J Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):61-8. PubMed ID: 18823713 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184 [TBL] [Abstract][Full Text] [Related]
17. MRI of prostate brachytherapy seeds at high field: a study in phantom. Thomas SD; Wachowicz K; Fallone BG Med Phys; 2009 Nov; 36(11):5228-34. PubMed ID: 19994533 [TBL] [Abstract][Full Text] [Related]